ArticleJournal of global health2025
Estimating the economic burden of respiratory syncytial virus infection among children <2 years old seeking care in North-West Nigeria.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The economic burden of respiratory syncytial virus and other acute respiratory infections among children <2 years old seeking care at a tertiary facility in Accra, Ghana.Journal of global health · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Respiratory syncytial virus (RSV) disease burden is highest in low- and middle-income countries; yet data for costs of RSV-related illness in these settings are scarce. We estimated RSV costs of illness to inform decision-making for RSV preventive strategies in Nigeria. Methods: This prospective study assessed the costs of care per episode of (severe) acute respiratory infection during one RSV season (April to November 2023). Children <2 years old, were recruited at tertiary inpatient and outpatient facilities in North-West Nigeria and grouped as non-severe (outpatient), severe (inpatient non-intensive care), and life-threatened (intensive care or fatality) cases. Direct medical, direct non-medical, and indirect cost data were collected using caregiver questionnaires at the index visit or day of admission and follow-up and gathered from hospital records at discharge. We summarised average costs in 2023 USD. Results: We included 792 children (mean age 8.7 months) with non-severe (n = 692), severe (n = 52), and life-threatening (n = 48) respiratory infections. Among these groups we confirmed RSV infection in 130 (19%), 19 (37%), and 14 (29%) children. The average societal costs were USD 13 (95% confidence interval (CI) = 11-14), USD 244 (95% CI = 198-290), and USD 179 (95% CI = 120-239) per episode of non-severe, severe, and life-threatening RSV infection, respectively. Costs associated with RSV did not increase stepwise with the severity categories due to small group sizes and fatalities with low costs included in the life-threatened group. For severe RSV, average household costs were over 200% of the national monthly minimum wage. Most households (89%) resorted to personal savings to cover costs. Conclusions: In young children in Nigeria, RSV presented a significant health and economic burden. This study can inform health economic evaluations of emerging RSV pharmaceutical interventions for Nigeria and may be adjusted for rural/urban contexts and level of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.